Expert Reviews Current State of CLL Treatment
onclive.cmail20.com/t/ViewE...
-
Danielle Brander, MD, highlights how recent advances are changing the field of chronic lymphocytic leukemia and what it means for patients and their oncologists.
onclive.cmail20.com/t/j-l-n...
-
Regimen Shows Potential for Reducing TLS Risk in CLL
Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.
onclive.cmail20.com/t/j-l-n...
-
Umbralisib Shows Promise in Relapsed/Refractory CLL
Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.
onclive.cmail20.com/t/j-l-n...
-
Addressing the Unmet Needs for the Treatment of CLL
Susan M. O’Brien, MD, discusses the unmet needs in the treatment and management of patients with chronic lymphocytic leukemia.
onclive.cmail20.com/t/j-l-n...
-
Evaluating Pharmacologic Agents in Relapsed/Refractory CLL
Michael Choi, MD, elucidates essential indications and considerations for treating relapsed/refractory chronic lymphocytic leukemia (CLL) with approved pharmacologic agents.
onclive.cmail20.com/t/j-l-n...
-
Popular on OncLive
Key Characteristics Emerging for CAR T Cell Success
An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.
Ibrutinib Slow but steady foreward movement.
CAR-T for CLL Hits Goal of Mid-Stage Trial - All patients had progressed on BTK inhibitors & most had failed venetoclax - MedPageToday, 6/12
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
